研究者情報
検索ページ

（最終更新日：2025-10-07 15:51:15）   スナカワ　ユウ   SUNAKAWA YU   砂川　優    所属   医学部医学科 臨床腫瘍学    職種   主任教授

■ 学術雑誌 1. 原著　 Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. 2025/10 2. 原著　 A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study) 2025/09 3. 原著　 Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction Cancer 2025/09 4. 原著　 Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. 2025/07 5. 原著　 Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR. 2025/05 6. 原著　 Real-World Genomic Landscape of Gastrointestinal Cancers in Asia and the Middle East Using Comprehensive Circulating Tumor DNA Next-Generation Sequencing. 2025/05 7. 原著　 Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. 2025/04 8. 原著　 Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study 2025/03 9. 原著　 Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. 2025/03 10. 症例報告　 A case of multiple bone metastases during the course of non-invasive bladder and prostate cancer 2025/02 11. 総説・解説　 FOLFOXIRI 療法 2024/12 12. 原著　 Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial. 2024/11 13. 総説・解説　 大腸がんにおける免疫療法と分子標的治療の併用 2024/11 14. 原著　 Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. 2024/09 15. 原著　 Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. 2024/09 16. 総説・解説　 切除不能な進行・再発胃癌に対する薬物療法の新展開 2024/09 17. 原著　 Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations. 2024/08 18. 原著　 Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. 2024/08 19. 原著　 Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08) 2024/08 20. 原著　 Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. 2024/07 21. 原著　 Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians 2024/07 22. 原著　 Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study 2024/07 23. 総説・解説　 Microsatellite instability: A 2024 update. 2024/06 24. 総説・解説　 腸内細菌と胃癌 2024/06 25. 原著　 An approach for improvement of the accuracy of cancer gene panel testing 2024/05 26. 原著　 The molecular landscape of gastric cancers for novel targeted therapies from real-world genomic profiling. 2024/05 27. 原著　 Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan 2024/04 28. 原著　 Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. 2024/04 29. 原著　 Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID) 2024/04 30. 原著　 Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer 2024/02 31. 原著　 Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. 2024/01 32. 原著　 Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. 2024/01 33. 原著　 Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials 2023/12 34. 原著　 Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study 2023/12 35. 原著　 Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study 2023/11 36. 原著　 Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16 2023/10 37. 原著　 Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study 2023/09 38. 総説・解説　 Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment 2023/08 39. 原著　 Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. 2023/06 40. 原著　 Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment 2023/06 41. 原著　 The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer 2023/06 42. 原著　 A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. 2023/05 43. 原著　 Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer. 2023/05 44. 原著　 Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. 2023/05 45. 原著　 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. 2023/05 46. 原著　 Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. 2023/05 47. 原著　 Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. 2023/05 48. 原著　 A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09). 2023/04 49. 原著　 Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer 2023/04 50. 原著　 Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. 2023/01 51. 原著　 Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study 2022/12 52. 原著　 Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies. 2022/10 53. 原著　 Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors 2022/10 54. 原著　 Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). 2022/06 55. 原著　 Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. 2022/05 56. 原著　 NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN) 2022/05 57. 原著　 Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. 2022/05 58. 原著　 The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. 2022/05 59. 原著　 Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. 2022/04 60. 原著　 The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study 2022/04 61. 原著　 Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers 2022/03 62. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2022/03 63. 原著　 Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. 2022/02 64. 原著　 Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) 2022/01 65. 症例報告　 切除不能胃癌に対してSP療法後にConversion　Surgery　を施行し長期生存が得られた1例 2021/12 66. 原著　 Prediction of esophagogastric varices associated with oxaliplatin administration 2021/11 67. 総説・解説　 The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer 2021/10 68. 原著　 Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cance 2021/08 69. その他　 REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. 2021/06 70. 総説・解説　 化学療法 2021/05 71. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2021/03 72. 総説・解説　 Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives 2021/03 73. 症例報告　 Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report 2020/11 74. 原著　 Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients 2020/10 75. 原著　 Early tumor shrinkage and depth of response in the second-line treatment for KRAS exon2 wild-type metastatic colorectal cancer: An exploratory analysis of the randomized phase 2 trial comparing panitumumab and bevacizumab in combination with FOLFIRI (WJOG6210G) 2020/09 76. その他　 REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. 2020/09 77. 原著　 RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer 2020/07 78. 原著　 Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer 2020/04 79. 症例報告　 "Phantom Akathisia" in an Amputated Leg of a Sarcoma Patient: A Case Report 2020/03 80. 原著　 Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients 2020/02 81. 総説・解説　 ICIsの適応にならない患者が、その治療を望む時ーインフォームドコンセントをどう行うか？ 2020/02 82. 原著　 Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. 2019/09 83. 原著　 Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors 2019/09 84. 原著　 DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer 2019/07 85. 原著　 Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer 2019/06 86. 総説・解説　 Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019/04 87. 原著　 Co-operative groups in the development of chemotherapy for gastric cancer. (Review Article (Invited)) 2019/03 88. 原著　 Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer 2018/12 89. 総説・解説　 dMMR/MSI-H大腸がんの治療 2018/11 90. 原著　 Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer 2018/10 91. 総説・解説　 クリニカルシークエンスを基にした分子標的治療の展開 2018/07 92. 総説・解説　 大腸がんに対する臨床開発と方向性 2018/07 93. 総説・解説　 DNAミスマッチ修復欠損またはMSI-highと免疫チェックポイント阻害薬効果の相関 2018/06 94. 原著　 A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11 2018/04 95. 原著　 Prognostic impact of FOXF1 polymorphisms in gastric cancer patients 2018/04 96. 原著　 A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. 2018/02 97. 原著　 CEA response and depth of response (DpR) to predict clinical outcomes of first-line cetuximab treatment for metastatic colorectal cancer 2017/12 98. 原著　 Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib 2017/12 99. 総説・解説　 膵がんにおけるFOLFIRINOX療法の試験 2017/12 100. 原著　 "Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib" 2017/11 101. 原著　 Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. 2017/11 102. 原著　 Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. 2017/09 103. 総説・解説　 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09 104. 総説・解説　 抗EFGR抗体薬を使うべき症例、ひとまず様子をみるべき症例 2017/08 105. 総説・解説　 大腸がんに対する臨床開発と方向性 2017/07 106. その他　 進行大腸がんにおいて原発部位が左側の患者では生存期間が長い 2017/07 5件表示 全件表示(106件)

■ 著書 1. 部分執筆　 消化器がん治療におけるctDNAの現状と展望「医学のあゆみ」 2024/01 2. 部分執筆　 FOLFOX+CET/PANI療法, FOLFIRI+CET/PANI療法「ガイドラインに沿った大腸癌薬物療法の要点と盲点」 2023/10 3. 部分執筆　 消化管がん（食道、胃、大腸）診療におけるゲノム医療の位置づけ「腫瘍内科」 2023/06

■ 学会発表 1. 化学療法が奏功した縦郭進展を伴う胸椎原発悪性骨巨細胞腫の1例 （口頭発表） 2025/09/20 2. Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13) （ポスター） 2025/07/04 3. Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC) （ポスター） 2025/07/04 4. Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18) （ポスター） 2025/07/04 5. 通過障害合併StageIVB食道癌に対するICI併用化学療法の実用的第2相試験 （口頭発表） 2025/06/27 6. An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19). （ポスター） 2025/06 7. Genomic landscape and biomarker analyses utilizing circulating-tumor DNA in advanced esophageal squamous cell carcinoma: Sub-analysis of SCRUM-MONSTAR GOZILA. （ポスター） 2025/06 8. Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials. （口頭発表） 2025/06 9. Survival impact of NeoRAS wild-type metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy. （ポスター） 2025/06 10. A phase 2 study of mFOLFOX6 plus nivolumab for untreated advanced esophageal squamous-cell cancer: FLONTALE trial （ポスター） 2025/03/08 11. MONSTAR-SCREEN-2における組織および血液に基づく遺伝子解析を用いた神経内分泌腫瘍の分子学的特徴 （口頭発表） 2025/03/08 12. リスク因子を有するBRAF変異型大腸癌に対するエンコラフェニブ、ビニメチニブ、セツキシマブ併用療法:BEETS試験 (JACCRO CC-18) （口頭発表） 2025/03/08 13. 進行性大腸癌に対するRAS/BRAF変異別のCGP検査の臨床的意義 （ポスター） 2025/03/08 14. RAS野生型大腸癌におけるmodified-FOLFOXIRI+セツキシマブ療法の効果予測臨床因子: DEEPER試験 (JACCRO CC-13) （口頭発表） 2025/03/07 15. 血中遊離DNAによりHER2遺伝子増幅が認められた固形がんに対するトラスツズマブ デルクステカンの多施設共同臨床第II相試験(HERALD/EPOC1806試験) データ アップデート （口頭発表） 2025/03/07 16. HER2遺伝子変異を有する固形癌に対するMobocertinib+T-DM1併用療法の安全性と有効性を検討する多施設共同第Ia/Ib相バスケット試験(WJOG16022M:HER2 Sand) （口頭発表） 2025/03/06 17. Random Surivival ForestによるStage III治癒切除胃癌患者の予後予測-START-2試験データを用いた後方視的研究- （口頭発表） 2025/03/06 18. リスク因子を有するBRAF変異型大腸癌に対するエンコラフェニブ、ビニメチニブ、セツキシマブ併用療法:BEETS試験 (JACCRO CC-18) （口頭発表） 2025/03/06 19. 再発胃癌・胃食道接合部癌におけるActionableな遺伝子異常の変化と臨床的特徴 （口頭発表） 2025/03/06 20. 膵癌の細胞診検体を用いたデジタルPCRによるKRAS変異同定の臨床的妥当性の検討 （口頭発表） 2025/03/06 21. 通過障害合併Stage IVB食道癌における免疫チェックポイント阻害薬併用化学療法の実用的第2相試験 （ポスター） 2025/03/06 22. がん領域における遠隔医療・遠隔治験に対する患者・医療従事者の声～アンケート調査結果より～ （口頭発表） 2025/02/28 23. A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). （ポスター） 2025/01 24. Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer. （ポスター） 2025/01 25. Encorafenib and cetuximab with/without binimetinib therapies for patients with BRAF-mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18). （ポスター） 2025/01 26. Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). （口頭発表） 2025/01 27. Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial. （ポスター） 2025/01 28. An Observational Study of BRAF Inhibitor Combination Therapy for BRAF-mutated Metastatic Colorectal Cancer Patients: Real-World Evidence from BEETS Trial (JACCRO CC-18) （口頭発表） 2024/10/26 29. Final results of the JACCRO CC-16:ramucirumab plus FOLFIRI for RAS wild-type anti-EGFR antibody refractory metastatic colorectal cancer （口頭発表） 2024/10/26 30. 再発胃癌における原発腫瘍と再発腫瘍のゲノムプロファイルの違い：Liquid-GEAR （口頭発表） 2024/10/26 31. ARCAD Asiaデータベースを活用した解析の実例 （口頭発表） 2024/10 32. Guradant360 CDxがん遺伝子パネル検査の初期成績 -20例の経験から- （口頭発表） 2024/10 33. 膵癌患者における細胞診検体の ddPCR 解析を用いた KRAS 変異測定 （口頭発表，一般） 2024/10 34. Genomic profile differences between primary and recurrent tumors in recurrent gastric cancer: the Liquid-GEAR Study （口頭発表） 2024/09/20 35. 胃癌患者におけるニボルマブの新規予後予測バイオマーカーとしての血中OXPHOS 関連遺伝子シグネチャーとSNPs （口頭発表） 2024/09/20 36. Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody （ポスター） 2024/09 37. 当院における”胆道・膵臓病センター”の設置から現在までのと今後の課題 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2024/07/25 38. 切除不能進行再発大腸癌（mCRC）における血漿を用いた包括的ゲノムプロファイリング（CGP）のRAS/BRAF変異別の意義 （口頭発表） 2024/07/12 39. 通過障害を合併したStage IVB食道癌に対する治療選択と臨床転帰の評価 （ポスター） 2024/07/04 40. A case of multiple bone metastases during the course of non-invasive bladder and prostate cancer （ポスター，一般） 2024/06/27 41. A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamous-cell cancer: FLONTALE trial （ポスター） 2024/06/27 42. Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab （ポスター） 2024/06/27 43. Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR （ポスター） 2024/06/27 44. Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13) （ポスター） 2024/06/27 45. A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2 （ポスター） 2024/06 46. Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703). （ポスター） 2024/06 47. Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M) （ポスター） 2024/06 48. Clinical characteristics and impact of bleeding complications in cancer-related isolated distal deep vein thrombosis: The ONCO DVT study （ポスター，一般） 2024/03/09 49. 再発した胃癌・胃食道接合部癌における リキッドバイオプシーのCGP検査：Liquid-GEAR試験 A liquid biopsy-based CGP testing in recurrent gastric or GEJ cancer: Liquid-GEAR study （口頭発表） 2024/03/01 50. Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17 （口頭発表） 2024/02/24 51. Clinical significance of plasma-based comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status （口頭発表，一般） 2024/02/24 52. Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13) （口頭発表） 2024/02/24 53. がん患者および医療従事者を対象とした腫瘍内科領域における遠隔医療に関する意識調査－医療従事者からの回答結果報告－ （口頭発表） 2024/02/24 54. ゲノムガイドシステムを用いた包括的がんゲノムプロファイリングの実装データの構築 （口頭発表） 2024/02/24 55. 患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査 （口頭発表） 2024/02/24 56. A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy （口頭発表） 2024/02/22 57. Clinical course of skin rashes caused by neoadju-vant gemcitabine plus S-1 for resectable pancre-atic cancer （口頭発表） 2024/02/22 58. Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: A feasibility study （口頭発表） 2024/02/22 59. The clinical validity of droplet digital PCR to identify KRAS mutations using blood or cytology specimens in pancreatic cancer （口頭発表） 2024/02 60. Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy. （ポスター） 2024/01/20 61. Efficacy of biomarker-matched therapy in clinical trials for advanced gastrointestinal cancers: A pooled analysis of SCRUM-Japan studies. （ポスター） 2024/01/20 62. Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR). （ポスター） 2024/01/20 63. Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database. （ポスター） 2024/01/20 64. Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.  2024/01/20 65. A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial). （ポスター） 2024/01/18 66. 免疫チェックポイント阻害薬の効果は予測できるか？ （口頭発表） 2023/12/13 67. 切除不能進行再発大腸癌におけるがん遺伝子パネル検査の臨床実装 （口頭発表） 2023/11/10 68. A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial （ポスター） 2023/10/23 69. Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13) （口頭発表） 2023/10/22 70. The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer patients with RAS mutation negative in circulating-tumor DNA after 1st or 2nd-line chemotherapy （ポスター，一般） 2023/10/22 71. SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer （ポスター，特別・招待講演等） 2023/10/21 72. 免疫チェックポイント阻害薬による間質性肺炎に対する治療実態調査 （口頭発表） 2023/10/21 73. Cyber Oncologyを活用した進行胃癌治療のreal-world data 構築のための実行可能性研究 （口頭発表） 2023/10/20 74. がん診療におけるリアルワールドデータ（RWD）収集に関する多施設共同研究 （ポスター） 2023/10/20 75. がん種別の包括的ゲノムプロファイリング（CGP）検査に基づいた治療提案と治療到達性 （口頭発表，一般） 2023/10/19 76. 筋層非浸潤性膀胱癌および前立腺癌経過中に生じた多発骨転移一例 （口頭発表，一般） 2023/09/28 77. がん遺伝子パネル検査の解析成功率の向上を目的とした後方視的解析 （ポスター，一般） 2023/07/28 78. 切除可能膵頭部に対するNAC-GSについての現況と課題 （口頭発表，一般） 2023/07/21 79. Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO （口頭発表） 2023/07/01 80. RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17) . （口頭発表） 2023/07/01 81. NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study. （口頭発表） 2023/06 82. Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08). （ポスター） 2023/06 83. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806). （ポスター） 2023/06 84. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. （口頭発表） 2023/06 85. Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study. （ポスター） 2023/06 86. RAS野生型切除不能進行再発大腸癌に対するm-FOLFOXIRI+cetuximab vs. bevacizumabの生存解析: DEEPER試験(JACCRO CC-13). （口頭発表） 2023/03/18 87. A study to evaluate the clinical utility of stress data collection in cancer patients treated with chemotherapy （ポスター） 2023/03/17 88. がん薬物療法患者におけるストレスデータ収集の有用性に関する研究 （ポスター） 2023/03/17 89. RAS変異型切除不能進行・再発大腸癌患者における化学療法後のctDNA中RAS遺伝子変異ステータス：RASMEX study (JACCRO CC-17) （口頭発表） 2023/03/16 90. RAS野生型切除不能進行再発大腸癌に対する血中RAS変異と2次治療FOLFIRI+ramucirumab療法の効果: JACCRO CC-16AR. （口頭発表） 2023/03/16 91. 切除不能進行大腸癌におけるCDC37遺伝子発現のレゴラフェニブ療法の効果予測 （口頭発表） 2023/03/16 92. 抗EGFR抗体薬併用化学療法進行再発大腸癌患者に対する2次治療FOLFIRI/ラムシルマブ併用療法の第II相試験:JACCRO CC-16 Update解析. （口頭発表） 2023/03/16 93. Efficacy and safety of fruquintinib in Japanese patients with refractory metastatic colorectal cancer from FRESCO-2. （口頭発表） 2023/03 94. 胃癌患者における免疫関連有害事象の予測因子としての自己免疫疾患関連抗体の臨床的意義 （口頭発表） 2023/02/25 95. Treatment for elderly gastric cancer patients-Geriatric assessment and clinical outcomes- （口頭発表） 2023/02/24 96. 切除可能膵頭部癌に対するNAC-GSについての現況と課題 （口頭発表，一般） 2023/02/17 97. 初診時切除不能と判断したがConversion surgery後も長期生存している非乳頭部十二指腸癌の1例 （口頭発表，一般） 2023/02/17 98. 胃がん患者における腸内細菌叢と臨床的特徴の検討：SCRUM-Japan MONSTAR-SCREEN （口頭発表） 2023/02 99. 胃癌ゲノムプロファイリングによるdruggable alterationの同定 （口頭発表） 2023/02 100. 進行胃癌における腸内細菌関連バイオマーカー （口頭発表） 2023/02 101. 高齢胃癌患者における高齢者機能評価と臨床経過 （口頭発表） 2023/02 102. Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO. （ポスター） 2023/01 103. Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR. （ポスター） 2023/01 104. Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07). （ポスター） 2023/01 105. RAS 野生型切除不能大腸癌における二次治療FOLFIRI＋ラムシルマブ療法の前治療レジメン別の効果：JACCRO CC-16サブ解析 （口頭発表） 2022/10 106. RAS野生型大腸癌における血管新生因子と2次治療FOLFIRI+RAMの効果:JACCRO CC-16AR （口頭発表） 2022/10 107. TRUSTY試験における血管新生関連遺伝子とFTD/TPI+BEVの有効性の検討 （口頭発表） 2022/10 108. リアルワールドデータ（RWD）から見た小腸癌のゲノムランドスケープ （口頭発表） 2022/10 109. 当院における抗EGFR抗体薬投与患者に対する診察前面談の取り組み （口頭発表） 2022/10 110. 進行胃癌・大腸癌における治療前の血中循環腫瘍DNA検出の臨床的妥当性 （口頭発表） 2022/10 111. 食道扁平上皮癌・胃食道接合部癌におけるctDNAを用いた治療戦略 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2022/09/25 112. Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08). （ポスター） 2022/09 113. 臨床試験における遠隔同意について考える〜医療機関の導入・実施経験から〜 （口頭発表） 2022/09 114. An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18). （ポスター） 2022/07/01 115. 切除可能大腸がん高齢患者の高齢者機能評価と臨床経過 （ポスター） 2022/06/18 116. Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.  2022/06/06 117. Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. （ポスター） 2022/06/04 118. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC). （ポスター） 2022/06/04 119. Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16. （ポスター） 2022/06 120. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. （口頭発表） 2022/06 121. Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. （ポスター） 2022/06 122. 遠隔医療を用いた治験プレスクリーニング検査の実装 （口頭発表） 2022/04 123. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)  2022/03/02 124. Evaluation of annotations for cancer gene panel testing using a genome-guided system  2022/02/17 125. 遠隔医療を用いた治験プレスクリーニング検査の実装  2022/02/17 126. Exploratory analysis of baseline tumor burden in the TRUSTY study: Phase 2/3 study of 2nd-line FTD/TPI + BEV for mCRC. （口頭発表） 2022/02 127. FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13). （口頭発表） 2022/02 128. Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study(JACCRO CC-17). （ポスター） 2022/02 129. Somatostatin receptor: a potential new therapeutic target for primary mucinous neoplasm of the appendix. （口頭発表） 2022/02 130. 切除不能進行結腸直腸癌における分子標的治療薬投与前後の血清VEGF-A, VEGF-D, PlGFの変動:GI-SCREEN CRC Ukit. （口頭発表） 2022/02 131. 抗EGFR抗体薬併用化学療法に不応/不耐となった進行再発大腸癌患者に対する2次治療:FOLFIRI/ラムシルマブ併用療法の第II相試験:JACCRO CC-16. （口頭発表） 2022/02 132. Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).  2022/01/22 133. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)  2022/01/21 134. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.  2022/01/20 135. Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).  2022/01/20 136. A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16. （ポスター） 2022/01 137. An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17). （ポスター） 2022/01 138. Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. （ポスター） 2022/01 139. Genomic factors of gut microbiome associated with patient characteristics in gastric cancer: from the DELIVER trial (JACCRO GC-08)  2021/10/23 140. がん遺伝子パネル検査に基づいた治療提案と治療到達性 （口頭発表，一般） 2021/10/21 141. がん遺伝子パネル検査の解析精度向上に向けた取り組み （口頭発表，一般） 2021/10/16 142. がん遺伝子パネル検査の解析精度向上に向けた取り組み （口頭発表，一般） 2021/10/13 143. 胃癌における腸内細菌ゲノム情報と患者背景の関係：DELIVER 試験 （口頭発表，一般） 2021/10/01 144. Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing （ポスター，一般） 2021/09/21 145. Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC); Early efficacy results from GI-SCREEN CRC Ukit study （口頭発表，一般） 2021/09/17 146. Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: the DELIVER trial (JACCRO GC-08) （口頭発表，一般） 2021/07/03 147. A multicenter phase II trial of trifluridine/thipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody : the WJOG8916G trial  2021/06/30 148. 当院におけるがん遺伝子パネル検査の二次的所見に関する検討 （ポスター，一般） 2021/06/18 149. Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data （ポスター，一般） 2021/06/04 150. The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). （口頭発表，一般） 2021/06/04 151. 免疫チェックポイント阻害薬の免疫関連有害事象に対する治療前の抗体検査の意義. （口頭発表，一般） 2021/05/29 152. 免疫チェックポイント阻害薬による中枢神経領域の免疫関連有害事象に関する検討 （口頭発表，一般） 2021/05/22 153. 切除不能胃癌に対してＳＰ療法後にcomversion surgery を施行し、長期生存が得られた1例 （口頭発表，一般） 2021/05/21 154. Bi-weekly nab-paclitaxel and ramucirumab therapy for advanced gastric cancer: JACCRO GC-09 trial （口頭発表） 2021/03/04 155. Gene profiling of circulating tumor DNA (ctDNA) in RAS wild-type mCRC patients who are refractory to anti-EGFR antibody  2021/02/19 156. 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性  2021/02/19 157. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial. （ポスター） 2021/01/15 158. Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08)  2021/01/15 159. Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study. （口頭発表，一般） 2020/10/23 160. 高齢者胃癌に対する治療の工夫 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/10/22 161. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)  2020/09/20 162. Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer  2020/07/01 163. "胃がん患者を対象とした腸内細菌叢の大規模臨床研究における採便に関するアンケート調査"  2020/06/10 164. A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial) （ポスター） 2020/05/29 165. Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: real-world data from a large observational/translational study, JACCRO GC-08 (DELIVER trial) （ポスター） 2020/05/29 166. Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis （ポスター） 2020/05/29 167. A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. （ポスター） 2020/01/24 168. Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.  2020/01/24 169. RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC).  2020/01/24 170. Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.  2020/01/24 171. Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.  2020/01/24 172. Identification of Site-specific Genome Alterations in Metastatic Colorectal Cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.  2019/10/26 173. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients （口頭発表） 2019/10/24 174. Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial) （口頭発表） 2019/09/29 175. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors （口頭発表） 2019/07/20 176. ＜大腸がん診療における遺伝子関連検査等のガイダンス＞包括的ゲノムプロファイリング検査/リキッドバイオプシー （口頭発表） 2019/07/20 177. An observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial) （口頭発表） 2019/07/18 178. Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer （口頭発表） 2019/07/18 179. Update on phase II trial of cetuximab plus S–1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06 （口頭発表） 2019/07/18 180. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)  2019/07/02 181. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer  2019/07 182. Clinical verification of circulating tumor RNA (ctRNA) as novel pre-treatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): a biomarker study of the DEEPER trial （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/06 183. Genomic Alterations After EGFR Blockade in Patients with RAS Wild-Type Metastatic Colorectal Cancer: Combined Tissue and Blood-Based Analysis from SCRUM-Japan GI-SCREEN and GOZILA （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/06 184. High unbound plasma concentration of M-2, an active metabolite, is associated with shorter survival in patients with metastatic colorectal cancer who received regorafenib  2019/03/08 185. 胃がん栄養 （ポスター） 2019/03/08 186. Chemotherapy after progREssiVe dIsease of niVolumab thErapy (REVIVE study) （口頭発表） 2019/02/28 187. Chemotherapy after progREssiVe dIsease of niVolumab thErapy(REVIVE study)  2019/02/28 188. CEA response at 4 wks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with 1st-line cetuximab-based chemotherapy: a STEP-analysis in the JACCRO CC-05/06 trials.  2019/01 189. Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN  2019/01 190. REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).  2019/01 191. The parametric estimation procedure to predict long-term efficacy on survival from publication data of clinical trials for metastatic colorectal cancer (mCRC)  2019/01 192. A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial) （ポスター） 2018/12/14 193. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3 （ポスター） 2018/10/21 194. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer （ポスター） 2018/10/21 195. Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation （ポスター） 2018/10/21 196. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer （ポスター） 2018/10/20 197. Regorafenib療法のラーニングカーブ評価 （ポスター） 2018/07/20 198. The Nationwide Cancer Geome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Gastric Cancer Cohort  2018/07 199. Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.  2018/06 200. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).  2018/06 201. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer （ポスター） 2018/04 202. Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer.  2018/01 203. Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.  2018/01 204. The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.  2018/01 205. Dynamic changes in levels of gene mutations using circulating DNA and efficacy of 1st-line modified FOLFOXIRI plus bevacizumab for metastatic colorectal cancer harboring RAS mutation (JACCRO CC-11)  2017/09/08 206. Tumor sideness and enriched gene groups for efficacy of 1st-line cetuximab treatment in metastatic colorectal cancer  2017/09/08 207. CEA response and DpR (JACCRO CC-05/06)  2017/07/27 208. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27 209. JACCRO CC-11安全性  2017/07/27 5件表示 全件表示(209件)